Bevirimat (PA-457)

What is Bevirimat?
• Bevirimat is an experimental anti-HIV drug being developed by Panacos Pharmaceuticals. It is currently in Phase II clinical trials.

Panacos Announces Data from Phase 2b Trial of HIV Maturation Inhibitor Bevirimat (PA-457) - 3/07/08

New Maturation Inhibitor May Be More Potent than Bevirimat (PA-457) - 8/24/07

Maturation Inhibitor Bevirimat (PA-457) Demonstrates Good Anti-HIV Activity in Phase 2b Study - 6/22/07

Panacos Announces Disappointing Results for Bevirimat 1/12/07

Safety and Antiviral Activity of PA-457, the First-in-class Maturation Inhibitor: A 10-Day Monotherapy Study - 1/13//06

Maturation Inhibitor PA 457 from Panacos, Dosed Orally Once Daily and Active against Resistant Virus, Is Potential Breakthrough Drug Treatment for HIV - 8/24/05

New Anti-HIV Therapies from Existing and Novel Drug Classes - 3/07/05

FDA Grants Fast-Track Review Status to PA-457, First in a New Class of Anti-HIV Drugs - 2/14/05

New Anti-HIV Drug Candidate PA-457 Exhibits Potent Anti-HIV Activity Following a Single Dose in HIV Patients - 12/06/04

Maturation Inhibitor PA-457 Is a Potent Experimental Drug in a New Class of Anti-HIV Compounds - 12/06/04

FDA-Approved Treatments
for HIV/AIDS

Experimental Treatments
for HIV/AIDS